LifeCycle sells North American royalties for Fenoglide

08/21/2008 | Reuters

LifeCycle Pharma, a Danish biotech company, has sold the North American royalty stream from its drug Fenoglide to Cowen Healthcare Royalty Partners in a deal worth as much as $105 million. Fenoglide, a cholesterol-lowering treatment, entered the U.S. market this year through Sciele Pharma.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC